Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
June 23 2022 - 7:00AM
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
Company will report its third quarter fiscal 2022 financial results
on Thursday, June 30, 2022, before market open. The Company will
host a corresponding conference call and live webcast to discuss
the financial results and key topics including business strategy,
partnerships and regulatory and reimbursement processes, at 8:30
a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details:US/Canada Participant
Toll-Free Dial-In Number: (833) 614-1551US/Canada Participant
International Dial-In Number: (914) 987-7290United Kingdom
International Dial-In Number: 0800 0288 438United Kingdom Local
Dial-In Number: 0203 1070 289Conference ID: 1546327
Webcast Registration
link: https://edge.media-server.com/mmc/p/y3zwhkuk
For further information, please contact: |
|
|
|
Renalytix plc |
www.renalytix.com |
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
Alex Price / Nicholas Moore |
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
Gary Clarence / Daniel Adams |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780
or renalytix@walbrookpr.com |
|
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
|
|
|
CapComm Partners |
Tel: 415-389-6400 or investors@renalytix.com |
|
Peter DeNardo |
|
|
About RenalytixRenalytix (LSE:
RENX) (NASDAQ: RNLX) is the global founder and leader in the new
field of bioprognosis™ for kidney health. The company has
engineered a new solution that enables early-stage chronic kidney
disease progression risk assessment. The Company’s lead product,
KidneyIntelX™, has been granted Breakthrough Designation by the
U.S. Food and Drug Administration and is designed to help make
significant improvements in kidney disease prognosis, transplant
management, clinical care, patient stratification for drug clinical
trials, and drug target discovery
(visit www.kidneyintelx.com). For more information,
visit www.renalytix.com.
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Sep 2023 to Sep 2024